Covid-19 Press Releases

12.21.2020

Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine

12.21.2020

Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine

12.14.2020

Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2

12.12.2020

U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older

12.10.2020

Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.

12.02.2020

Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19

11.20.2020

Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine

11.18.2020

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

11.11.2020

Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2

10.06.2020

BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2

09.15.2020

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

09.12.2020

Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial